Bajaj Healthcare Gears Up for Q3 Reveal on 15th January; Check Key Expectations Here
Click and Sign Up to Get Live Updates on Q3 Results
Updated: 15 Jan 2026 • 11:11 am
Posted by:
Bajaj Healthcare, one of the most significant Indian conglomerates, is set to announce its Q3 results for FY26 on 15th January 2026. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT.
Bajaj Healthcare Q3 Results 2026 Preview
- Bajaj Healthcare's revenue is expected to be in the range of ₹246.99 crore, a 49.24% YoY decrease.
- Profit After Tax, or PAT, is projected to fall by 130% YoY.
- Bajaj Healthcare's EBITDA is expected to rise to ₹65.86 crore.
- Net profit at ₹2567.89 crore, a rise of 80% YoY
Bajaj Healthcare Share Performance
- Over the past six months, Bajaj Healthcare's share price has fallen by 9.97% to ₹287.20.
- Moreover, over the past year, the stock has increased by 5.30%.
- Despite this weak short-term performance, Bajaj Healthcare's stock has delivered a financially sound 33.94% return over the past 5 years.
- As of 14th January 2026, the stock traded at ₹287.30 per share.
Key Factors to Watch for Bajaj Healthcare
- Revenue & Segment Growth: Growth in core businesses like APIs, formulations, intermediates, and speciality products, especially exports and high‑margin segments, which drive top‑line momentum.
- Profitability & Margin Stability: Sustaining improvement in net profits and operating margins amid past volatility and competitive pricing pressures in the pharmaceutical sector.
- Regulatory Approvals & Product Pipeline: Progress in clinical trials, new drug approvals, and registrations in regulated markets that can open higher‑value opportunities.
- Financial Health & Debt Management: Debt levels, leverage ratios, and working capital efficiency, as ongoing deleveraging and cash‑flow improvement support long‑term stability.
Final Thoughts
Bajaj Healthcare will announce its Q3 FY26 results on 15th January 2026. Analysts expect strong revenue growth of 8% YoY, a 5.35% rise in PAT, and a 65.86% decline in EBITDA. Bajaj Healthcare focuses on developing, manufacturing, and supplying active pharmaceutical ingredients (APIs), intermediates, finished formulations, amino acids, and nutraceutical products for domestic and global pharmaceutical, nutraceutical, and food industries.
Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.
Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!
Recent Articles
Top 10 Penny Stocks in India | Penny Stocks to Buy in 2026
Best Stocks to Buy Today: Explore Best Stocks With Expected Trends
Milky Mist Dairy Foods IPO Details: Everything You Should Know about
Karbonsteel Engineering IPO GMP & Review: Should You Apply or Avoid?
Taurian MPS IPO GMP & Review: Should You Apply or Avoid?
Shringar House of Mangalsutra IPO GMP & Review: Apply or Avoid?
Dev Accelerator IPO GMP & Review: Apply or Avoid?
Recent Articles
TSMC Stock Decoded: Can the Taiwan Chipmaker Reach a $6.5 Trillion Valuation by 2030, Nearly Tripling From Today, and Is It a Buy for the Next Four Years?
2 November 2026
EAAA India Alternatives IPO Listing: Shares Debut at 0.63% Premium on NSE and BSE, Check Share Price
2 November 2026
ITI Share Price Hits 20% Upper Circuit at Rs 259.14 After Opening Flat: Up 111% in Five Years but Down 34% in a Year, So Is It Time to Book Profits or Hold?
2 November 2026
Sebi Backs Removal of LTCG for Foreign Investors, Says Report: What the Proposal Means, Why FPI Outflows Hit Rs 3.04 Lakh Crore in 2026 and What Changes for Indian Investors
2 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
TSMC Stock Decoded: Can the Taiwan Chipmaker Reach a $6.5 Trillion Valuation by 2030, Nearly Tripling From Today, and Is It a Buy for the Next Four Years?
EAAA India Alternatives IPO Listing: Shares Debut at 0.63% Premium on NSE and BSE, Check Share Price
ITI Share Price Hits 20% Upper Circuit at Rs 259.14 After Opening Flat: Up 111% in Five Years but Down 34% in a Year, So Is It Time to Book Profits or Hold?
Sebi Backs Removal of LTCG for Foreign Investors, Says Report: What the Proposal Means, Why FPI Outflows Hit Rs 3.04 Lakh Crore in 2026 and What Changes for Indian Investors
Binance Hack Explained: $6.3 Billion Stolen in 20 Minutes, About $3 Billion Frozen, FBI Names North Korea and What It Means for Bitcoin and Indian Crypto Investors
Popular this week
Sensex Options Hit a Record Daily Premium Turnover in October 2026, Up 53% to Rs 35,481 Crore, as Volatility Returned to Indian Markets
Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times